Ken Griffin Harrow Health, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$20.85 - $46.47 $587,970 - $1.31 Million	28,200 Added 14.45%	223,400 $10 Million
Q2 2024 Aug 14, 2024	BUY	$10.0 - $21.64 $1.41 Million - $3.05 Million	140,900 Added 259.48%	195,200 $4.08 Million
Q1 2024 May 15, 2024	BUY	$9.3 - $13.23 $206,460 - $293,706	22,200 Added 69.16%	54,300 $718,000
Q4 2023 Feb 14, 2024	BUY	$8.1 - $16.36 $53,460 - $107,976	6,600 Added 25.88%	32,100 $359,000
Q3 2023 Nov 14, 2023	SELL	$14.03 - $22.08 $1.06 Million - $1.66 Million	-75,400 Reduced 74.73%	25,500 $366,000
Q2 2023 Aug 14, 2023	BUY	$17.37 - $28.08 $300,501 - $485,783	17,300 Added 20.69%	100,900 $1.92 Million
Q1 2023 May 15, 2023	BUY	$13.84 - $21.46 $483,016 - $748,954	34,900 Added 71.66%	83,600 $1.77 Million
Q4 2022 Feb 14, 2023	BUY	$10.28 - $14.78 $144,948 - $208,398	14,100 Added 40.75%	48,700 $718,000
Q3 2022 Nov 14, 2022	BUY	$6.57 - $24.88 $227,322 - $860,848	34,600 New	34,600 $418,000

176

21.4M

845K

717K

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $1.06B
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.